67.5 B-
Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
FDA Approved Research Chemical
Research Evidence 90.0/100
Safety Profile 45.0/100
155 Clinical Trials
Unknown: 34 PHASE4: 28 PHASE3: 26 PHASE2, PHASE3: 6 PHASE2: 26 PHASE1, PHASE2: 2 PHASE1: 13 NA: 17 EARLY_PHASE1: 3
- Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity Unknown Phase NOT_YET_RECRUITING Nantes University Hospital
- Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass Unknown Phase NOT_YET_RECRUITING University of Alberta
- Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea Unknown Phase NOT_YET_RECRUITING Novo Nordisk A/S
- A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China Unknown Phase NOT_YET_RECRUITING Novo Nordisk A/S
- The Effect of Semaglutide on the Intestinal Flora in Obesity Unknown Phase NOT_YET_RECRUITING Beijing Chao Yang Hospital
Showing 5 of 155 trials.
15 Research Papers
- Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes in Orthopaedic Surgery: A Scoping Review of Perioperative and Recovery Outcomes. J Am Acad Orthop Surg unknown
- Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease. Metab Syndr Relat Disord unknown
- Semaglutide for Aboriginal and Torres Strait Islander cardiovascular care: equity, cost and real-world hurdles. Intern Med J unknown
- Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies. Aliment Pharmacol Ther Review
- RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control. Endocr Connect unknown
Showing 5 of 15 papers by citation count.
FDA Data
Not FDA-Approved
Semaglutide has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is Semaglutide FDA approved?
No, Semaglutide has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has Semaglutide been studied in?
Semaglutide has been studied in 155 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Semaglutide?
Semaglutide has a CheckPeptides trust score of 67.5/100 (grade: B-). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- GLP-1 receptor agonist
- Molecular Weight
- 4114.0 Da
- PubChem
- CID 56843331 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 90.0/100
Safety Profile 45.0/100
Evidence Summary
- Clinical Trials
- 155
- Research Papers
- 15
- Trust Score
- 67.5/100
- Grade
- B-